Appeals Court Upholds Depomed Patents Asserted against Purdue Pharma
“This decision acknowledges the innovation of our patents and builds on our successful track record of aggressively enforcing our intellectual property estate,” said
"Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to our litigation against
OxyContin® is a registered trademark of Purdue.
INVESTOR AND MEDIA CONTACT:
Christopher KeenanVP, Investor Relations and Corporate Communications 510-744-8000
Minimum 15 minutes delayed.